CEO Linda Persson Summarises the First Quarter of 2025
NanoEcho’s Q2 report has now been published, and during the period several significant milestones have been achieved, strengthening the company’s position going forward. The first clinical study has been successfully completed, and alongside this, the first image of detected nanoparticles in a rectal lymph node has been published. The studies have also confirmed both the […]
NanoEcho wins tender and moves closer to its first revenues
On Thursday, 14 August, the fantastic news was announced that NanoEcho has won a public tender and has been appointed as the supplier of a research system to Lund University. The tender is a very important step towards generating the first revenues and forms part of the long-term strategy to gradually build up delivery and […]
Meet NanoEcho’s New Chairman of the Board – Björn Larsson
At the Annual General Meeting, Björn Larsson was elected as the new Chairman of the Board at NanoEcho. With an extensive background in global corporations as well as growth-stage companies within medtech, diagnostics, and precision medicine, he brings valuable leadership to the company. We asked Björn a few questions about what motivated him to join […]
NanoEcho awarded SEK 250,000 development grant
NanoEcho’s CEO, Linda Persson, together with senior software developer Martin Larsson, pitched to an expert panel appointed by Region Skåne with the aim of securing a development grant of SEK 250,000. We are now very pleased and proud to share the news that NanoEcho has been awarded the grant, which will be used to adapt […]
Significant Progress in the First Quarter of 2025
NanoEcho has published its interim report for the first quarter of 2025, highlighting several important advancements. The dose-confirmation study has been successfully completed with the primary endpoints achieved, and the collected data is now being used to optimise the system ahead of the next phase of the clinical programme. The rights issue carried out during […]
NanoEcho’s CEO and Clinical Director share more about the successfully completed study
NanoEcho’s clinical dose confirmation study has achieved its primary objectives according to the study’s design. This is a crucial milestone, indicating that the study has established an appropriate dose of the nanoparticle NEP-1 (ferumoxtran) as well as the time interval for the subsequent imaging examination. The study is the first clinical trial with NanoEcho’s imaging […]
CEO Linda Persson comments: Health-economic analysis of NanoEcho’s diagnostics accepted for publication in a leading journal
NanoEcho’s diagnostics have the potential to improve patients’ quality of life and reduce healthcare costs – now confirmed in a scientific article accepted for publication in the highly regarded journal PharmacoEconomics! The authors, including experts from IHE, the Institute for Health Economics, doctors from Skåne University Hospital, and representatives from NanoEcho, demonstrate in their analysis […]
CEO Linda Persson summarises 2024
Today, NanoEcho has published its Annual Report for 2024, a year of significant progress for NanoEcho! We have taken the crucial step from development to clinical phase, while also becoming a publicly listed company – milestones that strengthen our path towards commercialisation. In 2025, we will continue our clinical programme and take important steps towards […]
Interview with Ann-Christin Malmborg Hager – Board Member at NanoEcho
Meet Ann-Christin Malmborg Hager – an experienced board member with a strong background in transforming academic innovations into successful companies! With over 25 years of experience in developing companies based on academic ideas, Ann-Christin brings valuable strategic insight and business expertise. “NanoEcho addresses a significant medical need,” says Ann-Christin. “Imagine being diagnosed with rectal cancer and having […]
CEO Linda Persson Summarises the Fourth Quarter
Watch CEO Linda Persson summarise the fourth quarter, with a primary focus on the clinical study that started in October. Just before the end of the year, we were able to report that the study is progressing as planned and that half of the twelve planned participants have completed the study protocol. “For the first […]
